Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

BCC Research Analysis Forecasts Booming Generic Drug Market, Anticipated to Reach $655.8 Billion


Generic drugs, mirroring brand-name counterparts in composition and efficacy, offer affordable solutions for managing diverse health conditions, from hypertension to cardiovascular diseases. Fueled by expiring patents, a rising elderly population, and industry collaborations, the global market is thriving amid increasing demand and technological advancements.

BOSTON, March 5, 2024 /PRNewswire/ -- According to the latest BCC Research study, the demand for Global Markets for Generic Drugs is estimated to increase from $435.3 billion in 2023 to reach $655.8 billion by 2028, at a compound annual growth rate (CAGR) of 8.5% from 2023 through 2028.

BCC_Research_Logo

The comprehensive report delves into the global landscape of generic drugs, providing insights into market size and growth. It analyzes key national markets, offering a breakdown of the industry's current status and prospects. Encompassing both small molecule drugs and biosimilars, the report addresses drivers and challenges shaping the generic drug sector. A detailed competitive landscape outlines key players' sales and market rankings, while also highlighting emerging trends within the industry. Geographically, the market is segmented across North America, Europe, Asia-Pacific, and the Rest of the World, with specific countries detailed in each region. The estimations are grounded in drug manufacturers' total revenues, offering a comprehensive view of the market dynamics across varied regions.

In 2022, the combined impact of biosimilars and generics played a pivotal role in delivering substantial cost savings of over $400 billion to the U.S. healthcare system. Notably, generic companies, with a notable example being Viatris, are directing their attention towards cutting-edge technologies, particularly in the realm of complex injectables. These advancements underscore the industry's commitment to innovation and addressing the evolving healthcare landscape. However, despite these cost-saving measures and technological strides, the generic drug industry grapples with a highly fragmented nature marked by intense competition. This competitive landscape contributes to the challenge of maintaining robust profit margins, emphasizing the delicate balance generic companies must strike between affordability and sustainable business growth. The industry's continuous evolution in response to market dynamics is indicative of its resilience and determination to navigate complexities for the benefit of both healthcare providers and consumers.

Stay ahead of the curve with comprehensive insights into the expanding landscape of generic drug markets. Click here to Learn More.

Key Drivers of Global Markets for Generic Drugs

Increasing Patent Expirations and Loss of Exclusivity: The phenomenon of patent cliffs denotes the termination of patents protecting branded drugs, enabling the entry of generic versions into the market. Loss of exclusivity occurs when manufacturers of branded drugs lose legal safeguards against generic competition. These circumstances create opportunities for generic drug producers to enter the market, providing cost-effective alternatives for both consumers and healthcare providers.

Supportive Healthcare Policies: Governments and regulatory bodies worldwide have instituted policies that favor the development and utilization of generic drugs. These measures encompass offering incentives to generic drug manufacturers, minimizing entry barriers to the market, fostering price competition, advocating for the substitution of branded drugs with generics, and enhancing public awareness regarding the advantages of generic alternatives.

Evolving Physician Perspectives: Physicians, pivotal in prescribing medications, significantly influence the demand and acceptance of generics. Recent years have witnessed a shift in physician attitudes towards generics, driven by factors such as heightened evidence supporting their safety and efficacy, increased availability and diversity of generic options, growing pressure to curtail healthcare expenses, and expanded education and training on the merits of generic drugs.

Request a Sample Copy of the Global Markets for Generic Drugs Report.

Report Synopsis 

Report Metrics

Details

Base year considered

2022

Forecast Period considered

2023-2028

Base year market size

$407.2 billion

Market Size Forecast

$655.8 billion

Growth Rate

CAGR of 8.5% from 2023 through 2028

Segment Covered

By Molecule Type and Geographic Region

Regions covered

North America, Europe, Asia-Pacific, and Rest of the World (RoW)

Countries covered

U.S., Canada, Mexico, Germany, the U.K., Italy, China, India and Japan

Key Market Drivers

 

  • Increasing Patent Cliffs and Loss of Exclusivities
  • Favorable Healthcare Policies
  • Changing Physician Attitudes

 

Global Markets for Generic Drugs Segmentation:

Global Market for Generic Drugs, Breakdown by Molecule Type

This segment scrutinizes the market for generic drugs based on the type of molecule they originate from, distinguishing between small molecule generics and biosimilars. Small molecule generics, synthesized chemically, represent generic versions of branded drugs with well-established regulatory pathways, predominantly utilized in treating various diseases such as cardiovascular, central nervous system, respiratory, and infectious diseases. In contrast, biosimilars are generic counterparts of branded biologic drugs, featuring large, complex molecules derived from living organisms. Manufacturing biosimilars entails greater complexity and adherence to stringent regulatory requirements, and they find application in treating chronic and rare diseases like oncology, immunology, hematology, and endocrinology.

Global Market for Generic Drugs, Breakdown by Region

This segment dissects the market for generic drugs based on the geographic regions where they are sold. The primary regions include North America, Europe, Asia-Pacific, and the Rest of the World. North America, comprising the U.S., Canada, and Mexico, stands as the largest market, fueled by a high prevalence of chronic and infectious diseases, a robust healthcare infrastructure, favorable reimbursement scenarios, and the significant presence of key market players. Europe, encompassing Germany, the U.K., France, Italy, and others, represents the second-largest market, driven by a growing geriatric population, demand for personalized medicine, supportive regulatory frameworks, and increasing awareness of generic benefits. Asia-Pacific, inclusive of China, India, Japan, and other nations, emerges as the fastest-growing market, propelled by a large and expanding patient pool, rising disposable income, increased healthcare expenditure, and the adoption of advanced diagnostic technologies. The Rest of the World, covering Latin America, the Middle East, Africa, and other regions, constitutes the smallest market, characterized by lower diagnostic service penetration, a scarcity of skilled professionals, and limited resource availability.

This report on Global Markets for Generic Drugs provides comprehensive insights and analysis, addressing the following key questions:

  1. What is the projected market size and growth rate of the market?
    The generic drugs market is projected to grow from $407.2 billion in 2022 to $655.8 billion in 2028, at a compound annual growth rate (CAGR) of 8.5% during the forecast period.
  2. What are the key factors driving the growth of the market?
    The increasing number of patent cliffs and favorable regulatory policies are responsible for market growth.
  3. What segments are covered in the market?
    The generic drugs market is segmented on the molecule type and region.
  4. By Type, which segment will dominate the market by the end of 2028?
    Small molecule generics segment will dominate the market by the end of 2028.
  5. Which region has the highest market share in the market?
    Asia-Pacific has the highest market share.

Some of the Key Market Players Are:

Browse More Related Reports:

Global Markets for Vaccine Technologies: This comprehensive report delves into the dynamic landscape of human vaccines, focusing on key factors such as research and development spending, emerging technologies, and increasing competition shaping the market's trajectory. It examines the impact of new product launches, evolving lifestyles, and corporate strategies like mergers, acquisitions, and collaborations. Categories analyzed include pneumococcal, diphtheria, tetanus, HPV, MMR, and other vaccines, catering to various end users such as genomic research centers, academic institutions, and pharmaceutical companies. With detailed insights into market growth and geographic expansion opportunities, this study serves as a valuable resource for stakeholders ranging from industry players to government agencies and potential entrants seeking to navigate this rapidly evolving landscape.

Global Markets for Bioengineered Protein Drugs: This comprehensive report on the global market for bioengineered protein drugs aims to equip readers with both quantitative and qualitative insights, facilitating the development of effective business and growth strategies. Through thorough segmentation based on drug type, disease type, and region, the report enables readers to assess the market landscape, analyze their market position, and make informed business decisions concerning bioengineered protein drugs. The study delves into industry growth drivers, restraints, trends, and opportunities, offering a nuanced understanding of this dynamic market. Additionally, it provides a detailed examination of the competitive landscape, featuring comprehensive company profiles, and addresses the impact of COVID-19 on the bioengineered protein drug market. This report serves as a valuable resource for industry stakeholders, allowing them to navigate the complexities of the bioengineered protein drugs market with strategic foresight.

Directly Purchase a copy of the report with BCC Research.

For further information or to make a purchase, please get in touch with [email protected].

About BCC Research

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts' goal is to help you make informed business decisions, free of noise and hype.

Contact Us
Corporate HQ: BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, USA
Email: [email protected],
Phone: +1 781-489-7301

For media inquiries, email [email protected] or visit our media page for access to our market research library.

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. 

Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg

SOURCE BCC Research LLC


These press releases may also interest you

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIOŽ (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

18 avr 2024
Banco Latinoamericano de Comercio Exterior, S.A. , a Panama-based multinational bank originally established by the central banks of 23 Latin-American and Caribbean countries to promote foreign trade and economic integration in the Region, announced...



News published on and distributed by: